Using clinical datasets (CBioPortal), we saw that up to 20% of metastatic PC had changes in either MBTPS2 or its downstream SREBF, with upregulation of these genes significantly reducing overall survival (Fig. 2). This evidence concerns the gene MBTPS2 and pachyonychia congenita.